EntryPoint Capital’s IGM Biosciences IGMS Stock Holding History

EntryPoint Capital’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-15,801	Closed	-$152K	–	1230
2024 Q1	$152K	Buy	+15,801	New	+$183K	0.14%	212

Other funds holding IGMS

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EntryPoint Capital's IGMS Position: Q2 2024 in Review

EntryPoint Capital sold out of IGM Biosciences (IGMS) in Q2 2024, closing a stake of 15,801 shares — an estimated $152K sold.

EntryPoint Capital first reported a position in IGMS in Q1 2024 and held it in 1 quarter. The position peaked at $152K in Q1 2024. 82 funds tracked by Wall St. Rank hold IGMS as of Q2 2024.

EntryPoint Capital reported no remaining IGM Biosciences position as of Q2 2024 after selling out during the quarter.
EntryPoint Capital sold 15,801 IGM Biosciences shares in Q2 2024, an estimated $152K.
EntryPoint Capital first reported a position in IGM Biosciences in Q1 2024 and held it in 1 quarter.
EntryPoint Capital's IGM Biosciences position peaked at $152K in Q1 2024.
82 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.